Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3, indicating a new site build. This change appears to be a minor platform update and does not reflect changes to the study content on this page.SummaryDifference0.1%

- Check24 days agoChange DetectedThe site software revision was updated from v3.6.0 to v3.6.2, indicating a minor release. No changes to the study details or visible page content are introduced.SummaryDifference0.1%

- Check38 days agoChange DetectedThe page now indicates that recruitment is closed and adds new help/navigation sections. The Intervention/Treatment label is updated, and the revision footer shows v3.6.0 compared to v3.5.5.SummaryDifference0.5%

- Check45 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a new platform release. The change does not alter the study details or visible content on the page.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page displays Revision: v3.5.4, replacing the previous Revision: v3.5.3. This indicates a newer build of the page's interface without changes to the study information.SummaryDifference0.1%

- Check87 days agoChange DetectedThe page’s displayed software release/revision indicator was updated from v3.5.2 to v3.5.3, reflecting a website version change rather than any modification to the study record.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.